Iterum Therapeutics PLC (NASDAQ:ITRM) – Analysts at Svb Leerink lifted their Q2 2019 earnings estimates for shares of Iterum Therapeutics in a note issued to investors on Wednesday, May 15th, Zacks Investment Research reports. Svb Leerink analyst A. Fadia now anticipates that the company will post earnings per share of ($1.62) for the quarter, up from their previous forecast of ($1.75). Svb Leerink also issued estimates for Iterum Therapeutics’ Q3 2019 earnings at ($1.63) EPS, Q4 2019 earnings at ($1.32) EPS, FY2019 earnings at ($6.01) EPS, FY2020 earnings at ($2.81) EPS, FY2021 earnings at ($1.97) EPS and FY2022 earnings at ($0.80) EPS.
Several other research analysts have also recently weighed in on ITRM. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price target on shares of Iterum Therapeutics in a report on Monday, March 25th. Zacks Investment Research upgraded shares of Iterum Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a report on Thursday, March 28th. Finally, Royal Bank of Canada reduced their price target on shares of Iterum Therapeutics to $17.00 and set an “outperform” rating for the company in a report on Wednesday, May 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $17.00.
Iterum Therapeutics (NASDAQ:ITRM) last issued its earnings results on Tuesday, May 14th. The company reported ($1.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.09). Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 83.95%. The firm had revenue of $0.04 million during the quarter.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.